Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019

Therapeutics, Inc.
, a clinical-stage
biotechnology company pioneering a novel, immune-based approach to treat
solid tumor cancers through direct injection of its proprietary
therapeutic agents, today announced that a poster highlighting the
safety profile, tumor regression activity and immune activation of the
company’s lead product candidate, INT230-6, will be presented at the
American Society of Clinical Oncology (ASCO) Annual Meeting, taking
place May 31 to June 4, 2019 in Chicago.

Details of the poster presentation are as follows:

Title: Safety profile of INT230-6, a novel intratumoral
(IT) formulation, during injections into a variety of refractory
deep and superficial tumors with evidence of tumor regression and
immune activation

Abstract Number: 2602

Date/Time: Saturday, June 1, 2019, 8-11 a.m. CDT

Poster Session: Developmental Immunotherapy and Tumor

Presenter: Jacob Stephen Thomas, MD, Assistant Professor of
Clinical Medicine, University of Southern California


About INT230-6

INT230-6, Intensity’s lead product candidate designed for direct
intratumoral injection, is comprised of two proven, potent anti-cancer
agents and a penetration enhancer molecule that helps disperse the drugs
throughout tumors and diffuse into cancer cells. INT230-6 is being
evaluated in a Phase 1/2 clinical study (NCT03058289)
in patients with various advanced solid tumors. In preclinical studies,
INT230-6 eradicated tumors by a combination of direct tumor kill and
recruitment of dendritic cells to the tumor micro-environment that
induced anti-cancer T-cell activation. Treatment with INT230-6 in in
 models of severe cancer resulted in substantial improvement in
overall survival compared to standard therapies. Further, INT230-6
provided complete responder animals with long-term, durable protection
from multiple re-inoculations of the initial cancer and resistance to
other cancers. In mouse models, INT230-6 has shown strong synergy with
checkpoint blockage, including anti-PD-1 and anti-CTLA4 antibodies.
INT230-6 was discovered from Intensity’s DfuseRxSM platform.

About Intensity Therapeutics

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company
pioneering a new immune-based approach to treat solid tumor cancers.
Intensity leverages its DfuseRxSM technology platform to
create new drug formulations that, following direct injection, rapidly
disperse throughout a tumor and diffuse therapeutic agents into cancer
cells. Intensity’s product candidates have the potential to induce an
adaptive immune response that not only attacks the injected tumor, but
also non-injected tumors and unseen micro-metastases. INT230-6,
Intensity’s lead product candidate, is being evaluated in a Phase 1/2
clinical study in patients with various advanced solid tumors. For more
information, please visit www.intensitytherapeutics.com
and follow us on Twitter @IntensityInc.

Forward Looking Statements

This press release contains forward-looking statements regarding
Intensity Therapeutics’ plans, future operations and objectives. Such
statements involve known and unknown risks, uncertainties and other
factors that may cause actual performance or achievements to be
materially different from those currently anticipated. These
forward-looking statements include, among other things, statements about
the initiation and timing of future clinical trials.


Kerry Conlin
Investor Relations
[email protected]

Claire LaCagnina
6 Degrees
(315) 765-1462 [email protected]

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.